Search clinical trials for: CGC-11047 and erlotinib

Total 2713 results

University of Alabama at Birmingham
OSI Pharmaceuticals

Terminated

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Bristol-Myers Squibb

Completed

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, Spain, France, Argentina, Canada, Poland
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
Michael Prados
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Adult Brain Tumors

United States
Konstantin Dragnev
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Carcinoma, Non-small-cell Lung

United States
University of Cincinnati
Genentech, Inc.

Withdrawn

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Spain, Belgium, France, United Kingdom, Netherlands, Italy, Israel, Korea, Republic of
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Oncology Specialists, S.C.

Completed

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

Prostate Cancer

United States
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
University of Utah

Completed

A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Wu Jieping Medical Foundation
Zhejiang Cancer Hospital; Fudan University; Shanghai Chest Hospital; Shanghai Pulmonary... and other collaborators

Unknown

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment (ROLE)

Non Small Cell Lung Cancer, Oligometastatic

China
Zhejiang Cancer Hospital

Unknown

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0901)

Non-small Cell Lung Cancer

China
Hospital of Navarra
Dr. Enrique Martínez López

Unknown

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Lung Cancer Group Cologne

Unknown

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) (ERLOPET)

Carcinoma, Non-Small-Cell Lung

Germany
NCIC Clinical Trials Group
Roche Pharma AG

Completed

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

Canada
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Non-Squamous Non-Small Cell Lung Cancer

Italy
Northwell Health
Genentech, Inc.

Completed

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States
Northwestern University
OSI Pharmaceuticals

Withdrawn

Erlotinib for Treatment of Psoriasis

Psoriasis

United States
Alaunos Therapeutics

Unknown

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Advanced Solid Tumors

United States
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Ukraine, United Kingdom, United States, Bulgaria, Belgium, Germany, Hungary, Austria, Italy, Israel, Lithuania, Romania, Slovenia
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, India, Germany
Novartis Pharmaceuticals

Terminated

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Non-Small Cell Lung Cancer

Italy, Singapore, Spain, Germany, Korea, Republic of, United States, Belgium, France, Netherlands, Japan
Incyte Corporation

Withdrawn

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Solid Tumors and Hematologic Malignancy | NSCLC (Non-small Cell Lung Carcinoma)

United States
Kansas City Veteran Affairs Medical Center

Unknown

Erlotinib in Treating Patients With Barrett Esophagus

Esophageal Cancer | Precancerous Condition

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Massachusetts Institute of Technology
Massachusetts General Hospital

Not yet recruiting

Investigating the Effects of Cannabidiol on Social Anxiety Disorder (CAN-SAD)

Phobia, Social

United States
M.D. Anderson Cancer Center

Completed

Erlotinib in Combination With Cetuximab

Advanced Cancers

United States
Peter Kozuch
Hoffmann-La Roche; Genentech, Inc.

Terminated

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Andrew B Lassman, MD
Genentech, Inc.; OSI Pharmaceuticals

Completed

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Brain Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
Montefiore Medical Center
Genentech, Inc.

Completed

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Non-Small Cell Lung Cancer

United States
Pasi A. Janne, MD, PhD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaborators

Completed

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Adenocarcinoma | Non-small Cell Lung Cancer

United States
OSI Pharmaceuticals

Terminated

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Ependymoma

United States, Canada, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Sarcoma

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Bulgaria
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Non-Small Cell Lung Cancer

Finland
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

Non-Small Cell Lung Cancer

Italy, Spain, Netherlands, France, Germany, United Kingdom
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
Hoffmann-La Roche

Terminated

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Non-Small Cell Lung Cancer

United States, Canada, France, Poland
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Non Small Cell Lung Cancer

Greece
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan

Search clinical trials for: CGC-11047 and erlotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations